October 07, 2026 11:53 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
RBI shocks borrowers with first repo rate hike since 2023; rates raised to 5.50% | ‘Completely false’: Virat Kohli reacts to ₹5 crore claim over Premanand Maharaj visit | We’re watching it very closely: US urges Russia to share more information on plague situation | This isn’t about schools: Trump blames ‘mass migration’ and Islam for violent protests across France | ‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘Vote thief’ Gyanesh Kumar: Rahul Gandhi climbs barricade, waves Tricolour during explosive INDIA bloc protest | ‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘He should not have been flying’: JD Vance on Flydubai co-pilot | Israel was ready to shoot down Flydubai jet if it kept flying towards Tel Aviv: Reports | 'If law wasn't followed, we can undo it': Supreme Court's big warning on SIR process amid Gyanesh Kumar row
Image: UNI

MSN Labs launches Posaconazole (PosaOne) to treat Black fungus

| @indiablooms | May 22, 2021, at 12:21 am

Kolkata/IBNS: The drug-maker enterprise MSN Laboratories Pvt. Ltd. (MSN), introduced Posaconazole in India, under the brand name PosaOne, which is a triazole antifungal agent indicated for treating mucormycosis patients.

PosaOne contains both 100 mg delayed-release tablets & 300 mg injections. While the price of the tablet is Rs 600, the injections cost's a staggering Rs 8,500, according to The Hindu.

Many patients recovering from Covid 19 have been detected with a rare and deadly fungal infection known as mucormycosis or Black fungus. With mortality rates on the rise, accessibility of anti-fungal medication is being an unmet deficit in these testing times, MSN told.

The company officials mentioned that due to MSN’s competence in research and manufacturing of antifungal infection drugs, it is now targeting proactively to reach patients across India by ensuring the access of  PosaOne, through its distribution network & field force.

MSN has also developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units, company personnel informed, while also stating that the drug is approved by the Drug Controller General of India (DGCI) and matches the international quality standards.

As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules, recently, it also licensed Baridoz (Baricitinib) with Eli Lilly, MSN stated.

For availability of all COVID Drugs from MSN, patients can contact MSN COVID Helpline @ 91005 91030 or email customercare@msnlabs.com for further assistance.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.